Notice of Interim Results

RNS Number : 9426M
IXICO plc
03 May 2018
 

3 May 2018

 

IXICO plc

("IXICO" or the "Company")

 

Notice of Interim Results

 

IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, will announce its interim results for the six months ending 31 March 2018 on Wednesday 23 May 2018.

 

For further information please contact:

 

IXICO plc

Giulio Cerroni, Chief Executive Officer

Susan Lowther, Chief Financial Officer

 

Tel: +44 20 3763 7499

 

 

Shore Capital (Nomad and Broker)

Edward Mansfield/Anita Ghanekar

Tel: +44 20 7408 4090

 

 

FTI Consulting Limited (Investor Relations)

Simon Conway/Mo Noonan

Tel: +44 20 3727 1000

 

About IXICO

IXICO is the digital technologies company serving neuroscience.  Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance.  Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.

 

More information is available on www.IXICO.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORLLFIRELIFIIT

Companies

Ixico (IXI)
UK 100

Latest directors dealings